NINGBO INNO PHARMCHEM CO.,LTD. is proud to present an in-depth look at Ticagrelor, a critical compound in modern cardiovascular medicine. As a leading supplier, we understand the importance of detailed information for healthcare professionals and researchers alike. Ticagrelor is an orally active, reversible P2Y12 receptor antagonist, a class of drugs known for their efficacy in preventing thrombotic events. Its primary mechanism of action involves preventing adenosine diphosphate (ADP) from binding to the P2Y12 receptor on platelets, thereby inhibiting platelet activation and aggregation. This crucial function significantly reduces the risk of heart attack, stroke, and other cardiovascular complications.

The clinical applications of Ticagrelor are extensive, particularly in the management of Acute Coronary Syndrome (ACS) and Coronary Artery Disease (CAD). In patients with ACS, Ticagrelor, typically administered with aspirin, demonstrably lowers the incidence of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction (MI), and stroke. For individuals with CAD who are at high risk for these events, Ticagrelor offers a vital preventative measure. Understanding the ticagrelor P2Y12 receptor antagonist mechanism is key to appreciating its therapeutic value.

For those seeking to buy ticagrelor raw material, NINGBO INNO PHARMCHEM CO.,LTD. offers high-quality, pharmaceutical-grade product. Our commitment to purity ensures that researchers and manufacturers have access to a reliable API. The compound, identified by its CAS number 274693-27-5, is a white or off-white powder, meeting stringent specifications for its intended use. The effectiveness of Ticagrelor in preventing stroke with ticagrelor further solidifies its importance in clinical practice.

The safety profile of Ticagrelor, while generally favorable, includes potential side effects such as bleeding and dyspnea. Awareness of these is crucial for patient management. Interactions with other medications, particularly those affecting CYP3A4 metabolism or P-glycoprotein transport, must be carefully considered. Our focus on providing comprehensive information, including details on ticagrelor mechanism of action and ticagrelor for acute coronary syndrome, aims to support informed decision-making in healthcare and research. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to advancing cardiovascular health through the provision of high-quality pharmaceutical ingredients.